October 25, 2017 Synthetic Biologics to Report Third Quarter 2017 Operational Highlights and Financial Results on November 1, 2017
September 12, 2017 Synthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing
August 29, 2017 Synthetic Biologics Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017
August 3, 2017 Synthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results
July 27, 2017 Synthetic Biologics to Report Second Quarter 2017 Operational Highlights and Financial Results on August 3, 2017
June 27, 2017 Synthetic Biologics Announces Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
May 11, 2017 SYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Prevention of Clostridium difficile Infection
May 4, 2017 Synthetic Biologics Reports First Quarter 2017 Operational Highlights and Financial Results
April 26, 2017 Synthetic Biologics to Report First Quarter 2017 Operational Highlights and Financial Results on May 4, 2017
April 19, 2017 Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussis in Neonatal Animal Study
